Home Healthcare Healthcare Services Oncology Clinical Trials Market

Oncology Clinical Trials Market Size, Share & Trends Analysis Report By Phase (Phase I, Phase II, Phase III, Phase IV), By Type (Breast Cancer, Melanoma Cancer, Colorectal Cancer, Prostate Cancer, Lung Cancer, Others), By Study (Interventional studies, Observational studies, Expanded access studies) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Last Updated: July 24, 2026 | Author: Debashree B | Format:
Overview TOC Segmentation Methodology
Download Free Sample

Market Segmentation

  1. Oncology Clinical Trials Market, By Phase 2022-2034 (USD MILLION/ Units)
    1. Phase I
    2. Phase II
    3. Phase III
    4. Phase IV
  2. Oncology Clinical Trials Market, By Type 2022-2034 (USD MILLION/ Units)
    1. Breast Cancer
    2. Melanoma Cancer
    3. Colorectal Cancer
    4. Prostate Cancer
    5. Lung Cancer
    6. Others
  3. Oncology Clinical Trials Market, By Study 2022-2034 (USD MILLION/ Units)
    1. Interventional studies
    2. Observational studies
    3. Expanded access studies
  4. Regional Oncology Clinical Trials Market
    1. North America
      1. North America Oncology Clinical Trials Market By Phase 2022-2034 (USD MILLION/ Units)
        1. Phase I
        2. Phase II
        3. Phase III
        4. Phase IV
      2. North America Oncology Clinical Trials Market By Type 2022-2034 (USD MILLION/ Units)
        1. Breast Cancer
        2. Melanoma Cancer
        3. Colorectal Cancer
        4. Prostate Cancer
        5. Lung Cancer
        6. Others
      3. North America Oncology Clinical Trials Market By Study 2022-2034 (USD MILLION/ Units)
        1. Interventional studies
        2. Observational studies
        3. Expanded access studies
      4. U.S.
        1. Phase I
        2. Phase II
        3. Phase III
        4. Phase IV
        5. Breast Cancer
        6. Melanoma Cancer
        7. Colorectal Cancer
        8. Prostate Cancer
        9. Lung Cancer
        10. Others
        11. Interventional studies
        12. Observational studies
        13. Expanded access studies
      5. Canada
        1. Phase I
        2. Phase II
        3. Phase III
        4. Phase IV
        5. Breast Cancer
        6. Melanoma Cancer
        7. Colorectal Cancer
        8. Prostate Cancer
        9. Lung Cancer
        10. Others
        11. Interventional studies
        12. Observational studies
        13. Expanded access studies
    2. Europe
      1. Europe Oncology Clinical Trials Market By Phase 2022-2034 (USD MILLION/ Units)
        1. Phase I
        2. Phase II
        3. Phase III
        4. Phase IV
      2. Europe Oncology Clinical Trials Market By Type 2022-2034 (USD MILLION/ Units)
        1. Breast Cancer
        2. Melanoma Cancer
        3. Colorectal Cancer
        4. Prostate Cancer
        5. Lung Cancer
        6. Others
      3. Europe Oncology Clinical Trials Market By Study 2022-2034 (USD MILLION/ Units)
        1. Interventional studies
        2. Observational studies
        3. Expanded access studies
      4. U.K.
        1. Phase I
        2. Phase II
        3. Phase III
        4. Phase IV
        5. Breast Cancer
        6. Melanoma Cancer
        7. Colorectal Cancer
        8. Prostate Cancer
        9. Lung Cancer
        10. Others
        11. Interventional studies
        12. Observational studies
        13. Expanded access studies
      5. Germany
        1. Phase I
        2. Phase II
        3. Phase III
        4. Phase IV
        5. Breast Cancer
        6. Melanoma Cancer
        7. Colorectal Cancer
        8. Prostate Cancer
        9. Lung Cancer
        10. Others
        11. Interventional studies
        12. Observational studies
        13. Expanded access studies
      6. France
        1. Phase I
        2. Phase II
        3. Phase III
        4. Phase IV
        5. Breast Cancer
        6. Melanoma Cancer
        7. Colorectal Cancer
        8. Prostate Cancer
        9. Lung Cancer
        10. Others
        11. Interventional studies
        12. Observational studies
        13. Expanded access studies
      7. Spain
        1. Phase I
        2. Phase II
        3. Phase III
        4. Phase IV
        5. Breast Cancer
        6. Melanoma Cancer
        7. Colorectal Cancer
        8. Prostate Cancer
        9. Lung Cancer
        10. Others
        11. Interventional studies
        12. Observational studies
        13. Expanded access studies
      8. Italy
        1. Phase I
        2. Phase II
        3. Phase III
        4. Phase IV
        5. Breast Cancer
        6. Melanoma Cancer
        7. Colorectal Cancer
        8. Prostate Cancer
        9. Lung Cancer
        10. Others
        11. Interventional studies
        12. Observational studies
        13. Expanded access studies
      9. Russia
        1. Phase I
        2. Phase II
        3. Phase III
        4. Phase IV
        5. Breast Cancer
        6. Melanoma Cancer
        7. Colorectal Cancer
        8. Prostate Cancer
        9. Lung Cancer
        10. Others
        11. Interventional studies
        12. Observational studies
        13. Expanded access studies
      10. Nordic
        1. Phase I
        2. Phase II
        3. Phase III
        4. Phase IV
        5. Breast Cancer
        6. Melanoma Cancer
        7. Colorectal Cancer
        8. Prostate Cancer
        9. Lung Cancer
        10. Others
        11. Interventional studies
        12. Observational studies
        13. Expanded access studies
      11. Benelux
        1. Phase I
        2. Phase II
        3. Phase III
        4. Phase IV
        5. Breast Cancer
        6. Melanoma Cancer
        7. Colorectal Cancer
        8. Prostate Cancer
        9. Lung Cancer
        10. Others
        11. Interventional studies
        12. Observational studies
        13. Expanded access studies
      12. Rest of Europe
        1. Phase I
        2. Phase II
        3. Phase III
        4. Phase IV
        5. Breast Cancer
        6. Melanoma Cancer
        7. Colorectal Cancer
        8. Prostate Cancer
        9. Lung Cancer
        10. Others
        11. Interventional studies
        12. Observational studies
        13. Expanded access studies
    3. APAC
      1. APAC Oncology Clinical Trials Market By Phase 2022-2034 (USD MILLION/ Units)
        1. Phase I
        2. Phase II
        3. Phase III
        4. Phase IV
      2. APAC Oncology Clinical Trials Market By Type 2022-2034 (USD MILLION/ Units)
        1. Breast Cancer
        2. Melanoma Cancer
        3. Colorectal Cancer
        4. Prostate Cancer
        5. Lung Cancer
        6. Others
      3. APAC Oncology Clinical Trials Market By Study 2022-2034 (USD MILLION/ Units)
        1. Interventional studies
        2. Observational studies
        3. Expanded access studies
      4. China
        1. Phase I
        2. Phase II
        3. Phase III
        4. Phase IV
        5. Breast Cancer
        6. Melanoma Cancer
        7. Colorectal Cancer
        8. Prostate Cancer
        9. Lung Cancer
        10. Others
        11. Interventional studies
        12. Observational studies
        13. Expanded access studies
      5. Korea
        1. Phase I
        2. Phase II
        3. Phase III
        4. Phase IV
        5. Breast Cancer
        6. Melanoma Cancer
        7. Colorectal Cancer
        8. Prostate Cancer
        9. Lung Cancer
        10. Others
        11. Interventional studies
        12. Observational studies
        13. Expanded access studies
      6. Japan
        1. Phase I
        2. Phase II
        3. Phase III
        4. Phase IV
        5. Breast Cancer
        6. Melanoma Cancer
        7. Colorectal Cancer
        8. Prostate Cancer
        9. Lung Cancer
        10. Others
        11. Interventional studies
        12. Observational studies
        13. Expanded access studies
      7. India
        1. Phase I
        2. Phase II
        3. Phase III
        4. Phase IV
        5. Breast Cancer
        6. Melanoma Cancer
        7. Colorectal Cancer
        8. Prostate Cancer
        9. Lung Cancer
        10. Others
        11. Interventional studies
        12. Observational studies
        13. Expanded access studies
      8. Australia
        1. Phase I
        2. Phase II
        3. Phase III
        4. Phase IV
        5. Breast Cancer
        6. Melanoma Cancer
        7. Colorectal Cancer
        8. Prostate Cancer
        9. Lung Cancer
        10. Others
        11. Interventional studies
        12. Observational studies
        13. Expanded access studies
      9. Taiwan
        1. Phase I
        2. Phase II
        3. Phase III
        4. Phase IV
        5. Breast Cancer
        6. Melanoma Cancer
        7. Colorectal Cancer
        8. Prostate Cancer
        9. Lung Cancer
        10. Others
        11. Interventional studies
        12. Observational studies
        13. Expanded access studies
      10. South East Asia
        1. Phase I
        2. Phase II
        3. Phase III
        4. Phase IV
        5. Breast Cancer
        6. Melanoma Cancer
        7. Colorectal Cancer
        8. Prostate Cancer
        9. Lung Cancer
        10. Others
        11. Interventional studies
        12. Observational studies
        13. Expanded access studies
      11. Rest of Asia-Pacific
        1. Phase I
        2. Phase II
        3. Phase III
        4. Phase IV
        5. Breast Cancer
        6. Melanoma Cancer
        7. Colorectal Cancer
        8. Prostate Cancer
        9. Lung Cancer
        10. Others
        11. Interventional studies
        12. Observational studies
        13. Expanded access studies
    4. Middle East and Africa
      1. Middle East and Africa Oncology Clinical Trials Market By Phase 2022-2034 (USD MILLION/ Units)
        1. Phase I
        2. Phase II
        3. Phase III
        4. Phase IV
      2. Middle East and Africa Oncology Clinical Trials Market By Type 2022-2034 (USD MILLION/ Units)
        1. Breast Cancer
        2. Melanoma Cancer
        3. Colorectal Cancer
        4. Prostate Cancer
        5. Lung Cancer
        6. Others
      3. Middle East and Africa Oncology Clinical Trials Market By Study 2022-2034 (USD MILLION/ Units)
        1. Interventional studies
        2. Observational studies
        3. Expanded access studies
      4. UAE
        1. Phase I
        2. Phase II
        3. Phase III
        4. Phase IV
        5. Breast Cancer
        6. Melanoma Cancer
        7. Colorectal Cancer
        8. Prostate Cancer
        9. Lung Cancer
        10. Others
        11. Interventional studies
        12. Observational studies
        13. Expanded access studies
      5. Turkey
        1. Phase I
        2. Phase II
        3. Phase III
        4. Phase IV
        5. Breast Cancer
        6. Melanoma Cancer
        7. Colorectal Cancer
        8. Prostate Cancer
        9. Lung Cancer
        10. Others
        11. Interventional studies
        12. Observational studies
        13. Expanded access studies
      6. Saudi Arabia
        1. Phase I
        2. Phase II
        3. Phase III
        4. Phase IV
        5. Breast Cancer
        6. Melanoma Cancer
        7. Colorectal Cancer
        8. Prostate Cancer
        9. Lung Cancer
        10. Others
        11. Interventional studies
        12. Observational studies
        13. Expanded access studies
      7. South Africa
        1. Phase I
        2. Phase II
        3. Phase III
        4. Phase IV
        5. Breast Cancer
        6. Melanoma Cancer
        7. Colorectal Cancer
        8. Prostate Cancer
        9. Lung Cancer
        10. Others
        11. Interventional studies
        12. Observational studies
        13. Expanded access studies
      8. Egypt
        1. Phase I
        2. Phase II
        3. Phase III
        4. Phase IV
        5. Breast Cancer
        6. Melanoma Cancer
        7. Colorectal Cancer
        8. Prostate Cancer
        9. Lung Cancer
        10. Others
        11. Interventional studies
        12. Observational studies
        13. Expanded access studies
      9. Nigeria
        1. Phase I
        2. Phase II
        3. Phase III
        4. Phase IV
        5. Breast Cancer
        6. Melanoma Cancer
        7. Colorectal Cancer
        8. Prostate Cancer
        9. Lung Cancer
        10. Others
        11. Interventional studies
        12. Observational studies
        13. Expanded access studies
      10. Rest of MEA
        1. Phase I
        2. Phase II
        3. Phase III
        4. Phase IV
        5. Breast Cancer
        6. Melanoma Cancer
        7. Colorectal Cancer
        8. Prostate Cancer
        9. Lung Cancer
        10. Others
        11. Interventional studies
        12. Observational studies
        13. Expanded access studies
    5. LATAM
      1. LATAM Oncology Clinical Trials Market By Phase 2022-2034 (USD MILLION/ Units)
        1. Phase I
        2. Phase II
        3. Phase III
        4. Phase IV
      2. LATAM Oncology Clinical Trials Market By Type 2022-2034 (USD MILLION/ Units)
        1. Breast Cancer
        2. Melanoma Cancer
        3. Colorectal Cancer
        4. Prostate Cancer
        5. Lung Cancer
        6. Others
      3. LATAM Oncology Clinical Trials Market By Study 2022-2034 (USD MILLION/ Units)
        1. Interventional studies
        2. Observational studies
        3. Expanded access studies
      4. Brazil
        1. Phase I
        2. Phase II
        3. Phase III
        4. Phase IV
        5. Breast Cancer
        6. Melanoma Cancer
        7. Colorectal Cancer
        8. Prostate Cancer
        9. Lung Cancer
        10. Others
        11. Interventional studies
        12. Observational studies
        13. Expanded access studies
      5. Mexico
        1. Phase I
        2. Phase II
        3. Phase III
        4. Phase IV
        5. Breast Cancer
        6. Melanoma Cancer
        7. Colorectal Cancer
        8. Prostate Cancer
        9. Lung Cancer
        10. Others
        11. Interventional studies
        12. Observational studies
        13. Expanded access studies
      6. Argentina
        1. Phase I
        2. Phase II
        3. Phase III
        4. Phase IV
        5. Breast Cancer
        6. Melanoma Cancer
        7. Colorectal Cancer
        8. Prostate Cancer
        9. Lung Cancer
        10. Others
        11. Interventional studies
        12. Observational studies
        13. Expanded access studies
      7. Chile
        1. Phase I
        2. Phase II
        3. Phase III
        4. Phase IV
        5. Breast Cancer
        6. Melanoma Cancer
        7. Colorectal Cancer
        8. Prostate Cancer
        9. Lung Cancer
        10. Others
        11. Interventional studies
        12. Observational studies
        13. Expanded access studies
      8. Colombia
        1. Phase I
        2. Phase II
        3. Phase III
        4. Phase IV
        5. Breast Cancer
        6. Melanoma Cancer
        7. Colorectal Cancer
        8. Prostate Cancer
        9. Lung Cancer
        10. Others
        11. Interventional studies
        12. Observational studies
        13. Expanded access studies
      9. Rest of LATAM
        1. Phase I
        2. Phase II
        3. Phase III
        4. Phase IV
        5. Breast Cancer
        6. Melanoma Cancer
        7. Colorectal Cancer
        8. Prostate Cancer
        9. Lung Cancer
        10. Others
        11. Interventional studies
        12. Observational studies
        13. Expanded access studies
Report Details
−
200+ Trusted Partners
LG Electronics AMCAD Engineering KOBE STEEL LTD. Hindustan National Glass & Industries Limited Voith Group International Paper Hansol Paper Whirlpool Corporation Sony Samsung Electronics Qualcomm Google Fiserv Veto-Pharma Nippon Becton Dickinson Merck Argon Medical Devices Abbott Ajinomoto Denon Doosan Meiji Seika Kaisha Ltd LG Chemicals LCY chemical group Bayer Airrane BASF Toyota Industries Nissan Motors Neenah Mitsubishi Hyundai Motor Company Honda CRP Industries Inc pewag LGE Panasonic Lubrizol Corporation Leonardo Johnson & Johnson HB Fuller MITSUBISHI CHEMICAL Hyundai Mobis Amazon
Download Free Sample
Reach out to us
+1 646 905 0080 (U.S.)
+44 203 695 0070 (U.K.)
sales@straitsresearch.com

We are featured on:

Straits Research
Address:
105, Panchshil The Golden Bell,
Koregaon Park Annexe, Mundhwa,
Pune, Maharashtra 411036
Contact Us:
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)

sales@straitsresearch.com

Quick Links
Help
Verified. Protected. Secure.
Duns
DMCA.com Protection Status
lets-encrypt
Secure Payments:
Secure Payments
Follow Us:
www.straitsresearch.com © Copyright . All rights Reserved.